Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Sarcoma 1NET 1Head & Neck 1Gastrointestinal 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 37Breast Neoplasms 23Neoplasms 20Parkinson Disease 4, Autosomal Dominant Lewy Body 14Multiple Myeloma 14Neoplasm Metastasis 13Recurrence 10Melanoma 10Leukemia, Myeloid, Acute 10Colorectal Neoplasms 10Carcinoma, Renal Cell 10Lymphoma, Non-Hodgkin 9Leukemia, Lymphocytic, Chronic, B-Cell 9Urinary Bladder Neoplasms 8Lymphoma, Follicular 8Thyroid Neoplasms 7Hematologic Neoplasms 7Stomach Neoplasms 6Small Cell Lung Carcinoma 6Sarcoma 6Prostatic Neoplasms 6Ovarian Neoplasms 6Lymphoma, Mantle-Cell 6Lymphoma, B-Cell, Marginal Zone 6Lymphoma 6Lung Neoplasms 6Head and Neck Neoplasms 6Colonic Neoplasms 6Uterine Cervical Neoplasms 5Thyroid Cancer, Papillary 5

Interventions

tremelimumab 1repotrectinib 1osimertinib 1durvalumab 1Pemetrexed 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has announcements × Carcinoma × 1 year × Clear all
NCT03093116 2026-05-27

TRIDENT-1

Turning Point Therapeutics, Inc.

Phase 1/2 Recruiting
500 enrolled 2 FDA
EndocrineGastrointestinalHead & NeckNETSarcomaThoracic

Adenocarcinoma, Bronchial Neoplasms, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Colonic Diseases, Colonic Neoplasms, Digestive System Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Sarcoma, Thoracic Neoplasms, Thyroid Diseases, Thyroid Neoplasms, Neuroectodermal Tumors, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT03703297 2025-11-21

ADRIATIC

AstraZeneca

Phase 3 Active not recruiting
730 enrolled 19 charts 1 FDA
Thoracic

Carcinoma, Lung Neoplasms, Small Cell Lung Carcinoma

NCT04035486 2025-10-10

FLAURA2

AstraZeneca

Phase 3 Active not recruiting
587 enrolled 44 charts 1 FDA
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡